Citations

Clear

4201 citation(s) found for "Chen, Chen".

P4‐031: Integrative Network Analysis of Multiple Alzheimer's Disease Rnaseq Studies From the Accelerating Medicine Partnership‐Alzheimer's Disease Consortium
Zhang, Bin , Komashko, Vitalina, Mostafavi, Sara , Funk, Cory C. , Allen, Mariet , Amberkar, Sandeep , Hide, Winston, Schadt, Eric , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Logsdon, Ben , Chen, Mingming , Perumal, Thanneer Malai , Hide, Winston, Friend, Stephen , Bennett, David A. , Price, Nathan D. , Mangravite, Lara M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2120 Get It

P2‐243: Higher BMI is Associated with Greater Cerebral Glucose Metabolism in Late Middle‐Aged and Elderly Subjects Regardless of APOE ε4 Genotype
Weise, Christopher M., Chen, Yinghua , Goradia, Dhruman D., Savage, Cary R. , Caselli, Richard J. , Krakoff, Jonathan , Reiman, Eric M. , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_14 | Pages: No page available

10.1016/j.jalz.2016.06.1411 Get It

P4‐149: Peripheral Apoe Levels are Associated with Regional Gray Matter Volume, Cerebral Glucose Metabolism and Cognitive Performance in Cognitively Normal APOE E3/4 Carriers
Lee, Wendy , Chen, Yinghua , Reiman, Eric M. , Caselli, Richard J. , Nielsen, Henrietta M. , Chen, Kewei , Chen, Yinghua, Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_22 | Pages: No page available

10.1016/j.jalz.2016.06.2240 Get It

P3‐285: Patch‐Based Sparse Coding and Multivariate Surface Morphometry for Predicting Amnestic Mild Cognitive Impairment and Alzheimer’S Disease in Cognitively Unimpaired Individuals
Zhang, Jie , Li, Qingyang , Bauer, Robert, Reiman, Eric M. , Caselli, Richard J. , Stonnington, Cynthia M. , Wang, Yalin , Shi, Jie , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_19 | Pages: No page available

10.1016/j.jalz.2016.06.1939 Get It

Dataset for reporting of thymic epithelial tumours: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Detterbeck, Frank, Marx, Alexander , Roden, Anja C. , Marchevsky, Alberto M. , Mukai, Kiyoshi , Marino, Mirella , Bakker, Michael A. den , Yang, Woo‐Ick, Judge, Meagan , Hirschowitz, Lynn, Nicholson, Andrew G. , Chen, Gang

Mayo Clinic

Histopathology | October 14, 2016 | Volume: 70 | Issue: 4 | Pages: 522-538

10.1111/his.13099 | PMID 27735079 Get It

AimsThe International Collaboration on Cancer Reporting (ICCR) is a not‐for‐profit organization formed by the Royal Colleges of Pathologists of Australasia and the United Kingdom, the College of American Pathologists, the Canadian Association of Pathologists–Association Canadienne des Pathologists in association with the Canadian Partnership Against Cancer, and the European Society of Pathology. Its goal is to produce standardized, internationally agreed, evidence‐based datasets for use throughout the world.Methods and resultsThis article describes the development of a cancer dataset by the multidisciplinary ICCR expert panel for the reporting of thymic epithelial tumours. The dataset includes ‘required’ (mandatory) and ‘recommended’ (non‐mandatory) elements, which are validated by a review of current evidence and supported by explanatory text. Seven required elements and 12 recommended elements were agreed by the international dataset authoring committee to represent the essential information for the reporting of thymic epithelial tumours.ConclusionsThe use of an internationally agreed, structured pathology dataset for reporting thymic tumours provides all of the necessary information for optimal patient management, facilitates consistent and accurate data collection, and provides valuable data for research and international benchmarking. The dataset also provides a valuable resource for those countries and institutions that are not in a position to develop their own datasets.
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
Goss, Paul E. , Shepherd, Lois E. , Chapman, J. W. , Chen, Bingshu E. , Kubo, Michiaki , Furukawa, Yoichi , Momozawa, Yukihide , Stearns, Vered , Barman, Poulami , Weinshilboum, Richard M. , Kalari, Krishna R. , Wang, Liewei , Xie, Fang , Ingle, James N. , Xie, Fang , Ellis, Matthew J. , Chapman, Judith‐Anne W. , Pritchard, Kathleen I. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered , Chen, Bingshu E , Kalari, Krishna R

Mayo Clinic

Cancer Research | October 11, 2016 | Volume: 76 | Issue: 23 | Pages: 7012-7023

10.1158/0008-5472.can-16-1371 | PMID 27758888 Get It

Abstract Genetic risks in breast cancer remain only partly understood. Here, we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (AI) anastrozole and exemestane. Single-nucleotide polymorphisms (SNP) of top significance were identified in the gene encoding MIR2052HG, a long noncoding RNA of unknown function. Heterozygous or homozygous individuals for variant alleles exhibited a ∼40% or ∼63% decrease, respectively, in the hazard of breast cancer recurrence relative to homozygous wild-type individuals. Functional genomic studies in lymphoblastoid cell lines and ERα-positive breast cancer cell lines showed that expression from MIR2052HG and the ESR1 gene encoding estrogen receptor-α (ERα) was induced by estrogen and AI in a SNP-dependent manner. Variant SNP genotypes exhibited increased ERα binding to estrogen response elements, relative to wild-type genotypes, a pattern that was reversed by AI treatment. Further, variant SNPs were associated with lower expression of MIR2052HG and ERα. RNAi-mediated silencing of MIR2052HG in breast cancer cell lines decreased ERα expression, cell proliferation, and anchorage-independent colony formation. Mechanistic investigations revealed that MIR2052HG sustained ERα levels both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated, proteasome-dependent degradation of ERα. Taken together, our results define MIR2052HS as a functionally polymorphic gene that affects risks of breast cancer recurrence in women treated with AI. More broadly, our results offer a pharmacogenomic basis to understand differences in the response of breast cancer patients to AI therapy. Cancer Res; 76(23); 7012–23. ©2016 AACR.
A Case of Simultaneous Benign Metastasizing Leiomyomas and Disseminated Peritoneal Leiomyomatosis Following Endoscopic Power Morcellation for Uterine Disease
Park, Beau Y., Leslie, Kevin O., Vaszar, Laszlo T. , Cornella, Jeffrey L. , Chen, Longwen

Mayo Clinic

Female Pelvic Medicine & Reconstructive Surgery | September 30, 2016 | Volume: 23 | Issue: 1 | Pages: e1-e3

10.1097/spv.0000000000000342 | PMID 27748666 Get It

Abstract Extrauterine spread of leiomyomas is rare and most commonly occurs in the lungs. We present a case of simultaneous metastatic leiomyomatosis to the lungs and peritoneal cavity following laparoscopic myomectomy with power morcellation. The patient presented to our institution for further management where she underwent a robotically assisted hysterectomy with bilateral salpingo-oophorectomy. Leiomyomatous implants measuring up to 2.4 cm were resected from bowel mesentery and bladder peritoneum. Subsequent serial computed tomography imaging confirmed stable pulmonary nodules without new intraperitoneal lesions. Increasing number of cases involving extrauterine spread of leiomyomas has been reported with the introduction of power morcellation. The exact pathogenesis is unknown but is likely multifactorial. We emphasize that although the incidence of spread of benign disease is low, it is important to recognize this phenomenon as we will likely continue to encounter similar cases in the coming years.